Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Assertio Holdings, Inc. stock logo
ASRT
Assertio
$0.66
-3.7%
$0.66
$0.51
$1.80
$63.24M0.29534,143 shs151,355 shs
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
$0.48
-1.7%
$4.04
$3.36
$26.30
$4.49M1.51628,703 shs358,501 shs
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
$0.63
-0.2%
$0.69
$0.25
$4.71
$8.88M1.382.52 million shs3.57 million shs
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
$1.26
$1.07
$3.40
$30.33M0.2171,840 shs676,700 shs
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
$0.00
$0.07
$4.08
$3.50M2.57848,888 shs9.65 million shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Assertio Holdings, Inc. stock logo
ASRT
Assertio
-0.77%+4.48%+8.51%+8.95%-58.69%
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
0.00%+21.65%-0.06%+20.39%-55.05%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
+14.54%+62.06%-1.85%-25.78%-85.51%
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
0.00%0.00%0.00%0.00%-40.46%
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
0.00%0.00%0.00%0.00%+6,910.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Assertio Holdings, Inc. stock logo
ASRT
Assertio
1.8537 of 5 stars
3.50.00.00.02.20.81.3
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
N/AN/AN/AN/AN/AN/AN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
2.9952 of 5 stars
3.52.00.00.03.21.71.3
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Assertio Holdings, Inc. stock logo
ASRT
Assertio
3.00
Buy$2.75316.48% Upside
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
0.00
N/AN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
3.00
Buy$4.00536.23% Upside
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
3.00
Buy$14.00∞ Upside
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest MBRX, OCUP, AZRX, PHAS, and ASRT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2025
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
6/9/2025
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$4.00
5/19/2025
Assertio Holdings, Inc. stock logo
ASRT
Assertio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.50 ➝ $3.50
5/13/2025
Assertio Holdings, Inc. stock logo
ASRT
Assertio
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Assertio Holdings, Inc. stock logo
ASRT
Assertio
$124.96M0.51$0.05 per share14.08$1.27 per share0.52
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
N/AN/AN/AN/A($0.76) per shareN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/AN/AN/AN/A$1.77 per shareN/A
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
$16.45M0.00N/AN/A$2.20 per share0.00
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
$818K0.00N/AN/A($1.93) per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Assertio Holdings, Inc. stock logo
ASRT
Assertio
-$21.58M-$0.32N/A22.01N/A-25.72%-24.87%-10.87%8/6/2025 (Estimated)
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
-$32.67M-$11.50N/AN/AN/AN/A-482.96%-258.47%N/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-$21.76MN/A0.00N/AN/AN/A-278.80%-100.11%8/4/2025 (Estimated)
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
-$9.99M-$0.49N/AN/AN/A-85.75%-30.19%-27.55%N/A
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
-$131.07M-$2.13N/AN/AN/A-12,572.13%N/A-174.38%N/A

Latest MBRX, OCUP, AZRX, PHAS, and ASRT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-$0.42N/AN/AN/AN/AN/A
8/6/2025Q2 2025
Assertio Holdings, Inc. stock logo
ASRT
Assertio
-$0.06N/AN/AN/A$27.86 millionN/A
5/13/2025Q1 2025
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-$0.71-$0.69+$0.02-$0.69N/AN/A
5/12/2025Q1 2025
Assertio Holdings, Inc. stock logo
ASRT
Assertio
-$0.06-$0.14-$0.08-$0.14$27.52 million$26.49 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Assertio Holdings, Inc. stock logo
ASRT
Assertio
N/AN/AN/AN/AN/A
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
N/AN/AN/AN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/AN/AN/AN/AN/A
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
N/AN/AN/AN/AN/A
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Assertio Holdings, Inc. stock logo
ASRT
Assertio
0.36
1.66
1.35
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
N/A
1.33
1.33
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/A
1.35
1.35
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
N/A
10.68
10.68
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
N/A
0.47
0.47

Institutional Ownership

CompanyInstitutional Ownership
Assertio Holdings, Inc. stock logo
ASRT
Assertio
48.96%
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
6.27%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
15.52%
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
14.97%
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
49.02%
CompanyEmployeesShares OutstandingFree FloatOptionable
Assertio Holdings, Inc. stock logo
ASRT
Assertio
2095.78 million91.95 millionOptionable
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
129.33 million8.65 millionNot Optionable
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
2014.13 million13.83 millionNot Optionable
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
1425.92 million24.47 millionOptionable
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
6049.86 million44.92 millionNot Optionable

Recent News About These Companies

MedPharm appoints Bill Humphries as new CEO
Medpharm Appoints Chief Executive Officer
PhaseBio Pharmaceuticals Inc.
PhaseBio Pharmaceuticals, Inc. (PHASQ)
Modified Release Neurology Therapeutics Report 202…
Leading innovators in GLP-1 analogues for the pharmaceutical industry
Alcami Announces CEO Transition
8-K: PhaseBio Pharmaceuticals Inc
BioCryst Appoints Dr. Nancy Hutson as Chair of the Board

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Assertio stock logo

Assertio NASDAQ:ASRT

$0.66 -0.03 (-3.70%)
Closing price 04:00 PM Eastern
Extended Trading
$0.67 +0.01 (+1.47%)
As of 06:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

AzurRx BioPharma stock logo

AzurRx BioPharma NASDAQ:AZRX

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL.

Moleculin Biotech stock logo

Moleculin Biotech NASDAQ:MBRX

$0.63 0.00 (-0.22%)
Closing price 04:00 PM Eastern
Extended Trading
$0.63 +0.00 (+0.52%)
As of 06:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Ocuphire Pharma stock logo

Ocuphire Pharma NASDAQ:OCUP

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.

PhaseBio Pharmaceuticals stock logo

PhaseBio Pharmaceuticals NASDAQ:PHAS

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.